International Journal of Advances in Science, Engineering and Technology(IJASEAT)
.
Follow Us On :
current issues
Volume-12,Issue-1  ( Jan, 2024 )
Past issues
  1. Volume-12,Issue-1  ( Jan, 2024 )
  2. Volume-11,Issue-4  ( Oct, 2023 )
  3. Volume-11,Issue-3  ( Jul, 2023 )
  4. Volume-11,Issue-2  ( Apr, 2023 )
  5. Volume-11,Issue-1  ( Jan, 2023 )
  6. Volume-10,Issue-4  ( Oct, 2022 )
  7. Volume-10,Issue-3  ( Jul, 2022 )
  8. Volume-10,Issue-2  ( Apr, 2022 )
  9. Volume-10,Issue-1  ( Jan, 2022 )
  10. Volume-9,Issue-4  ( Oct, 2021 )

Statistics report
Apr
Submitted Papers : 80
Accepted Papers : 10
Rejected Papers : 70
Acc. Perc : 12%
  Journal Paper


Paper Title :
Comparison between Antipsychotic Drug and its Nano-Emulsion on Neurochemical and Behavioral Disorders on an Animal Model of Schizophrenia and its Adverse Effects

Author :A. M. Abd-Elrazek

Article Citation :A. M. Abd-Elrazek , (2018 ) " Comparison between Antipsychotic Drug and its Nano-Emulsion on Neurochemical and Behavioral Disorders on an Animal Model of Schizophrenia and its Adverse Effects " , International Journal of Advances in Science, Engineering and Technology(IJASEAT) , pp. 44-51, Volume-6, Issue-2, Spl. Iss-1

Abstract : Background: The present work was carried out to study the effect of olanzapine (OLZ) and its solid lipid nanoparticles (SLN) on ketamine-induced schizophrenic-like symptoms in albino rats. The study extended to evaluate the adverse effects of sub-chronic administration of the different doses of olanzapine and its solid lipid nanoparticles. Methods: To assess the effect of different doses of treatment on locomotor activity and cognitive impairment induced by ketamine open field and passive avoidance tests was carried out. Excitatory and inhibitory amino acids as well as dopamine and serotonin were estimated in brain regions. Immunohistochemical study of BCL2 was performed. Liver function, lipid profile and lipid peroxide, then assessed to evaluate the side effect. The results: administrations of OLZ-SLN at low and high doses before ketamine attenuated the behavioral abnormalities by inhibiting the ketamine-induced increased in glutamate, dopamine and serotonin levels and enhanced apoptosis in the studied brain areas. In addition, the sub-chronic treatment with OLZ-SLN showed no adverse effect while the treatment with OLZ free form did. Conclusion: The low and high dose of OLZ-SLN that equivalent to (1/10 and 1/20 from the therapeutic dose) blocked the effect of ketamine while the same doses of OLZ in free form cannot. Keywords - Solid lipid nanoparticles; Antipsychotic drugs; hepatotoxicity; Excitatory and inhibitory amino acids; Monoamines.

Type : Research paper

Published : Volume-6, Issue-2, Spl. Iss-1


DOIONLINE NO - IJASEAT-IRAJ-DOIONLINE-12204   View Here

Copyright: © Institute of Research and Journals

| PDF |
Viewed - 19
| Published on 2018-07-25
   
   
IRAJ Other Journals
IJASEAT updates
Volume-11,Issue-4 (Oct,2023)
The Conference World

JOURNAL SUPPORTED BY